Stamford, CT -- (SBWIRE) -- 12/07/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Trina Solar Limited (ADR) (NYSE:TSL), Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), GT Advanced Technologies Inc (NASDAQ:GTAT), Novavax, Inc. (NASDAQ:NVAX)
Trina Solar Limited (ADR) (NYSE:TSL) ended lower -5.91% from its previous close of $13.36 and complete the day at $12.57. The total number of shares changed hands during the day was 8.12 million. After opening at $13.52, the stock hit as high as $13.61. However, it traded between $2.76 and $17.84 over the last twelve months.
Stocks graphical chart shows a bearish trend during its last one month’s trading session. It remained positive +13.55% during the previous three months trade. Trina Solar Limited, an integrated solar-power products manufacturer, engages in the design, development, manufacture, and sale of photovoltaic (PV) modules worldwide. The company provides mono- and multi-crystalline silicon ingots, wafers, cells, and related products.
Has TSL Found The Bottom and Ready To Move Up? Find Out Here
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) closed yesterday at $21.64, a +11.95% increase. Around 7.43 million shares were traded, beating an-average trading volume of 871,512 shares. The company is now valued at around $1.07 billion. The stock opened the session at $19.35 and touched its highest price point at $22.00.
AUXL’s lowest price point for the session stood at $19.33 and its 52 week price range stood at $13.87 - $22.00. Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, focuses on developing and marketing pharmaceutical products in urology and sexual health worldwide. The company markets Testim for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a non-oral drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED.
For How Long AUXL’s Gloss will Attract Investors? Find out via this report
GT Advanced Technologies Inc (NASDAQ:GTAT) moved -2.47 percent lower at $8.67 and traded between $8.41 and $9.07 after opening the day at $8.99. Its performance over the last five days remained -11.62%, which stands at -11.98% for a month. Going back further than one month, 1-year performance after recent close was 186.14%.
The company has a total of 123.83 million outstanding shares and its total market capitalization is $1.07 billion. Its beta value stands at 1.23 times and earnings per share was -$1.71. GT Advanced Technologies Inc. provides crystal growth equipment and solutions for the solar, light emitting diode (LED), and electronics industries worldwide. The company operates through three segments: Polysilicon; Photovoltaic (PV); and Sapphire. The Polysilicon segment offers silicon deposition reactors; equipment, technology, and engineering services for the production and purification of trichlorosilane and silane; and engineering services.
Why Should Investors Buy GTAT After the Recent Fall? Just Go Here and Find Out
Novavax, Inc. (NASDAQ:NVAX)’s shares rose, +4.70 percent from its previous close of $4.23 to close at $4.23. The stock is up around 123.81% this year and 128.65% for the last 12 months. Around 7.25 million shares changed hands yesterday, higher from an-average trading volume of 3.85 million shares. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company?s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV).
Why Should Investors Buy NVAX After The Recent Gain? Just Go Here and Find Out
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)